Prelude Therapeutics (PRLD) stock, explained like you're 5

Is Prelude Therapeutics a small, medium or large cap company?

No. Prelude Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 310 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Prelude Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves PRLD stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround (Yahoo Finance UK)
• Citizens reiterates Prelude Therapeutics stock rating on Lilly deal (Investing.com)
• Lilly will supply two drugs for Prelude's planned breast cancer trial. (Stock Titan)
• Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear (Simply Wall Street)
• Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD) (Seeking Alpha)

Key terms to know before you follow PRLD

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility